The paper by Aimo et al. [1] reported in the current issue of the European Journal of Internal Medicine highlights a significant increase in the gamma-glutamyltransferase enzyme (GGT) in patients affected by transthyretin (TTR) related cardiac amyloidosis. The manuscript represents a very nice example of how progress in medicine proceeds. An accurate collection of clinical and biochemical data is essential to discover biomarkers suitable for studying the natural history of the disease and response to new therapies.
